Analysts May Have Underestimated Argenx SE's (ARGX) 5 year Revenue Growth

Argenx SE (NASDAQ:ARGX) is one of the 10 best NASDAQ growth stocks to buy for the next 10 years. According to a report released on January 21, Emily Bodnar of H.C. Wainwright maintained a Buy rating along with the price target of $915 on Argenx SE (NASDAQ:ARGX). The firm’s price target reflects a modest 8.93% upside from the current levels.

Additionally, on January 20, Wells Fargo reiterated its Buy rating on Argenx SE (NASDAQ:ARGX). However, Wells Fargo analyst Derek Archila raised the firm’s price target on the stock from $1,264 to $1,317, implying a further 55% upside from current levels.

In addition to the price target, the analyst also raised the firm’s Vyvgart revenue estimates for the 2026-2030 period by 5%-15%. This adjustment reflects Wells Fargo’s expectations for a stronger performance than previously anticipated. The firm highlighted that the FY 2026 consensus revenue estimate of $5.6 billion appears to underestimate the company’s growth potential. As per the firm’s estimates, the company could achieve $6.5 billion in revenue. This assumes single-digit QoQ growth in Q1, followed by low double-digit QoQ growth from Q2 through Q4.

Argenx SE (NASDAQ:ARGX) is a commercial-stage biopharmaceutical company. It develops various therapies for the treatment of autoimmune diseases across the Netherlands, the United States, China, Japan, and internationally. The company’s products include VYGART HYTRULO and VYGART. Argenx SE was founded in 2008 and is based in Amsterdam, the Netherlands.

While we acknowledge the potential of ARGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT:  Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy and 30 Most Fantastic Stocks Every Investor Should Pay Attention To.

Disclosure: None. This article is originally published at Insider Monkey.